Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment

NCT00623480 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00623480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00623480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2008
Completion date
November 30, 2013
Enrollment
84 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a